Epstein-barr virus infections in children after transplantation of the small intestine

American Journal of Surgical Pathology

Volumn 22, Issue 3, 1998, Pages 299-309

  Finn, Laura ^a   Reyes, Jorge ^a   Bueno, Javier ^a   Yunis, Eduardo ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Epstein Barr virus; Intestinal transplantation; Posttransplant lymphoproliferative disease; Rejection

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; TACROLIMUS; VIRUS RNA;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FEMALE; GASTROINTESTINAL BIOPSY; GRAFT REJECTION; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN SITU HYBRIDIZATION; INFANT; INTESTINE GRAFT; LYMPHOPROLIFERATIVE DISEASE; MALE; VIRUS INFECTION;

ADOLESCENT; AZATHIOPRINE; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; FEMALE; GRAFT REJECTION; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INTESTINE, SMALL; LYMPHOPROLIFERATIVE DISORDERS; MALE; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS; TUMOR VIRUS INFECTIONS;

EID: 0031933997     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000478-199803000-00004     Document Type: Article

References (47)

1. Abu-Elmagd K, Fung JJ, Reyes J, et al. Management of intestinal transplantation in humans. Transplant Proc 1992;24:1243-4.
2. Abu-Elmagd K, Todo S, Tzakis A, et al. Three years clinical experience with intestinal transplantation. J Am Coll Surg 1994;179:385-400.
3. Chang KL, Chen Y-Y, Shibata D, Weiss LM. Description of an in situ hybridization methodology for detection of Epstein-Barr virus RNA in paraffin-embedded tissues, with a survey of normal and neoplastic tissues. Diagn Mol Pathol 1992;1:246-55.
4. Cockfield SM, Preiksaitis J, Harvey E, et al. Is sequential use of ALG and OKT3 in renal transplants associated with an increased incidence of fulminant posttransplant lymphoproliferative disorder? Transplant Proc 1991;23:1106-7.
5. Craig FE, Gulley ML, Banks PM. Posttransplant lymphoproliferative disorders. Am J Clin Pathol 1993;99:265-76.
6. Deamant FD, Albujar PF, Chen Y-Y, Weiss LM. Epstein-Barr virus distribution in nonneoplastic lymph nodes. Mod Pathol 1993;6:729-32.
7. Dousset B, Hubscher S, Padbury R, et al. Acute liver allograft rejection - is treatment necessary? Transplantation 1993;55:529-34.
8. Frizzera G, Hanto DW, Gajl-Peczalska KJ, et al. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res 1981;41:4262-79.
9. Grant D. Current results of intestinal transplantation. Lancet 1996;347:1801-3.
10. Green M, Reyes J, Jabbour N, et al. Use of quantitative PCR to predict onset of Epstein-Barr viral infection and post-transplant lymphoproliferative disease after intestinal transplantation in children. Transplant Proc 1996;28:2759-60.
11. Hanto DW, Frizzera G, Purtilo DT, et al. Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res 1981;41:4253-61.
12. Hanto DW, Sakamoto K, Purtilo DT, Simmons RL, Najarian JS. The Epstein-Barr virus in the pathogenesis of posttransplant lymphoproliferative disorders. Surgery 1981;90:204-13.
13. Ho M, Jaffe R, Miller G, et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 1988;45:719-27.
14. Ho M, Miller G, Atchison RW, et al. Epstein-Barr virus infections and DNA hybridization studies in posttransplant lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis 1985;152:876-86.
15. Hubscher SG, Williams A, Davison SM, Young LS, Niedobitek G. Epstein-Barr virus in inflammatory diseases of the liver and liver allografts: an in situ hybridization study. Hepatology 1994;20:899-907.
16. Jaffe R, Trager JDK, Zeevi A, Sonmez-Alpan E, Dequesnoy R. Multivisceral intestinal transplantation: surgical pathology. Pediatr Pathol 1989;9:633-54.
17. Knowles D, Cesarman E, Chadburn A, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995;85:552-65.
18. Langnas AN, Shaw BW, Antonson DL, et al. Preliminary experience with intestinal transplantation in infants and children. Pediatrics 1996;97:443-8.
19. Lee ES, Locker J, Nalesnik M, et al. The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. N Engl J Med 1995;332:19-25.
20. Lee RG, Nakamura K, Tsamandas AC, et al. Pathology of human intestinal transplantation. Gastroenterology 1996;110:1820-34.
21. Montone KT, Hodinka RL, Salhany KE, Lavi E, Rostami A, Tomaszewski JE. Identification of Epstein-Barr virus lytic activity in post-transplantation lymphoproliferative disease. Mod Pathol 1996;9:621-30.
22. Montone KT, Hodinka RL, Tomaszewski JE. Identification of Epstein-Barr virus lytic and latent RNA transcripts in post-transplant lymphoproliferative disorder. Int J Surg Pathol 1995;3:119-30.
23. Morrison VA, Dunn DL, Manivel JC, Gajl-Peczalska KJ, Peterson BA. Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med 1994;97:14-24.
24. Nalesnik M, Starzl T. Epstein-Barr virus, infectious mononucleosis, and posttransplant lymphoproliferative disorders. Transplant Sci 1994;4:61-79.
25. Nalesnik MA, Jaffe R, Starzl TE, et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 1988;133:173-92.
26. Nalesnik MA, Makowka L, Starzl TE. The diagnosis and treatment of posttransplant lymphoproliferative disorders. Curr Prob Surg 1988;25:367-472.
27. Niedobitek G, Herbst H, Young LS, et al. Patterns of Epstein-Barr virus infection in non-neoplastic lymphoid tissue. Blood 1992;79:2520-6.
28. Purtilo DT, Strobach RS, Okano M, Davis JR. Epstein-Barr virus-associated lymphoproliferative disorders. Lab Invest 1992;67:5-23.
29. Randhawa PS, Jaffe R, Demetris AJ, et al. Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1-gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med 1992;327:1710-4.
30. Randhawa PS, Yousem SA, Paradis IL, Dauber JA, Griffith BP, Locker J. The clinical spectrum, pathology and clonal analysis of Epstein-Barr virus-associated lymphoproliferative disorders in heart-lung transplant recipients. Am J Clin Pathol 1989;92:177-85.
31. Rao AS, Fontes P, Zeevi A, et al. Augmentation of chimerism in whole organ recipients by simultaneous infusion of donor bone marrow cells. Transplant Proc 1995;27:210-2.
32. Renard TH, Andrews WS, Foster ME. Relationship between OKT3 administration, EBV seroconversion, and the lymphoproliferative syndrome in pediatric liver transplant recipients. Transplant Proc 1991;23:1473-6.
33. Revillon Y, Jan D, Sarnacki S, Goulet O, Brousse N, Ricour C. Intestinal transplantation in the child: experimental and clinical studies. J Pediatr Surg 1993;28:292-8.
34. Reyes J, Abu-Elmagd K, Tzakis A, et al. Infectious complications after human small bowel transplantation. Transplant Proc 1992;24:1249-50.
35. Reyes J, Green M, Bueno J, et al. Epstein Barr virus associated posttransplant lymphoproliferative disease after intestinal transplantation. Transplant Proc 1996;28:2768-9.
36. Riddler SA, Breinig MC, McKnight JLC. Increased levels of circulating Epstein-Barr virus (EBV) - infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 1994;84:972-84.
37. Rogers BB, Conlin C, Timmons CF, Dawson DB, Krisher K, Andrews WS. Epstein-Barr Virus PCR correlated with viral histology and serology in pediatric liver transplant patients. Pediatr Pathol Lab Med 1997;17:391-400.
38. Rowe DT, Qu L, Reyes J, et al. Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Micro Biol 1997;35:1612-5.
39. Savoie A, Perpete C, Carpentier L, Joncas J, Alfieri C. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood 1994;83:2715-22.
40. Shapiro R, Tzakis A, Scantlebury V, et al. Improving results of pediatric renal transplantation. J Am Coll Surg 1994;179:424-32.
41. Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporine-steroid therapy. Lancet 1984;1:584-7.
42. Steiber AC, Boillot O, Scotti-Foglieni C, et al. The surgical implications of the posttransplant lymphoproliferative disorders. Transplant Proc 1991;23:1477-9.
43. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990;323:1723-8.
44. Todo S, Reyes J, Furukawa H, et al. Outcome analysis of 71 clinical intestinal transplantations. Ann Surg 1995;222:270-82.
45. White FV, Reyes J, Jaffe R, Yunis EJ. Pathology of intestinal transplantation in children. Am J Surg Pathol 1995;19:687-98.
46. Winters G, Loh E, Schoen F. Natural history of focal moderate cardiac allograft rejection. Is treatment warranted? Circulation 1995;91:1975-80.
47. Yousem SA. Significance of clinically silent untreated mild acute cellular rejection in lung allograft recipients. Hum Pathol 1996;27:269-73.